## Chromium

<table>
<thead>
<tr>
<th>Atomic number</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atomic weight</td>
<td>51.99</td>
</tr>
</tbody>
</table>

### Collection

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Volume</th>
<th>Container Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole blood</td>
<td>2 mL</td>
<td>Plastic tube - EDTA or heparin</td>
</tr>
<tr>
<td>Serum/Plasma</td>
<td>2 ml</td>
<td>Plastic tube - plain, EDTA or heparin</td>
</tr>
<tr>
<td>Urine</td>
<td>20 mL</td>
<td>Sterile Universal</td>
</tr>
</tbody>
</table>

Use Trace Elements Certified tubes

### Reference ranges

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Unit</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum/plasma</td>
<td>nmol/L</td>
<td>Less than 6</td>
</tr>
<tr>
<td>Blood</td>
<td>nmol/L</td>
<td>Less than 15</td>
</tr>
<tr>
<td>Urine</td>
<td>nmol/L</td>
<td>8.7</td>
</tr>
<tr>
<td></td>
<td>nmol/L</td>
<td>15.4</td>
</tr>
<tr>
<td></td>
<td>nmol/24 h</td>
<td>8.7</td>
</tr>
<tr>
<td></td>
<td>nmol/mmol creatinine</td>
<td>2.85</td>
</tr>
</tbody>
</table>

### References

Clinical

Chromium occurs in several oxidation states, mainly as chromium(3) and chromium(6). Chromium and chromium compounds are widely used in a number of industrial processes, such as chrome plating, pigment production, timber impregnation and photography.

Chromium is an essential trace element which, although reasonably abundant in the environment, is present in the human body in relatively small amounts. Measurement of the element is difficult in view of the low concentrations and the possibility of contamination. The intestinal absorption of inorganic chromium is about 2%, but is more bioavailable when present as an organic complex. Chromium is thought to be transported in the blood bound to transferrin.

Deficiency

Chromium deficiency was first documented in animals when it resulted in impaired glucose tolerance. Deficiency of an organic complex of chromium, the so-called glucose tolerance factor, was considered to be responsible. Glucose tolerance factor has not been isolated, but was suggested to be a complex of chromium with glutathione and nicotinic acid. Human deficiency was only revealed by the increasing use of total parenteral nutrition (TPN) where patients presumed to be deficient in this element developed insulin resistance and neuropathy. In animals chromium deficiency has also been shown to impair growth and fertility and to be associated with hypercholesterolaemia.

The US dietary guideline for adequate daily chromium intake is 30–35 µg (adult male) and to 20–25 µg (adult female).

In clinical practice there is some evidence that diabetes mellitus and hypercholesterolaemia may be associated with chromium deficiency, and evidence that supplementation may improve these conditions. Other salts of chromium, such as chromium picolinate, have been shown to have a beneficial effect on glucose metabolism.

Toxicity

Chromium salts may have acute and chronic effects, producing both corrosive damage to mucus membranes and skin (‘chrome ulcers’), and also allergic responses. A serious long-term effect is the increased incidence of malignancy in respiratory organs amongst workers inhaling chromium dust or fumes. There may also be an increased incidence of gastrointestinal tumours.

Chromium(6) is a well documented carcinogen and mutagen. Chromium is a listed environmental contaminant.

Surgical implants

Much of the recent clinical interest in chromium and cobalt arises from the use of a chromium/cobalt/molybdenum alloy in orthopaedic implants, especially hip replacements. Chromium and cobalt and the main components of the alloys used in many of these implants, but other metals are also present. Chromium and cobalt are primarily released from wear on metal-on-metal surfaces. The
most important of these is the surface between a metal cup in the pelvis and a metal ball. The release of metal is due to friction at the surface, which can be due to misalignment of the components and can lead to failure of the implant. If uncorrected there can be severe local tissue damage with formation of a ‘pseudo tumour’ and necrosis of soft tissue. There have been two warnings on these implants from the UK MHRA suggesting that patients may need to be followed up for the life of the implant. Recent evidence suggests that other surfaces may also contribute to metal release, especially the junction between the stem in the femur and the ball in modular implants. After revision surgery chromium concentrations may remain high for some considerable time due to chromium accumulation in soft tissue surrounding the implant, whereas cobalt does not accumulate.

The UK MHRA suggest that a concentration of 7 ug/L (135 nmol/L) is indicative of increased wear of the implant. Slightly lower concentrations have been proposed by other works and a European multidisciplinary group.

In almost all patients there is no evidence of toxicity from metal release in these patients. There has been some concern about possible carcinogenicity, but evidence to date suggests that there is no increased cancer risk in these patients.

The same alloys are used in other implants, such as knee and other joints, but the hip is the only implant with a metal-on-metal surface, so the metal release is less important in these implants.

**Laboratory Indices**

**Surgical Implants.** Measurement of serum or blood chromium concentration is the best available index of excess exposure from surgical implant, and concentrations may still be high some weeks after the incident. Urine chromium concentrations decline rapidly after removal from exposure, but appropriately collected samples are suitable for occupational monitoring. The MHRA advice recommends that whole blood is used for monitoring patients with metal-on-metal implants. There are differences between blood and serum, but blood will give the total circulating metal concentration, although both can be used.

**Nutritional assessment.** For the assessment of deficiency, please note the special sampling precautions that need to be taken. The considerable doubt regarding nutritional requirements for chromium, and the variable concentration of contaminating chromium in TPN fluids, suggest that regular monitoring of serum chromium in patients receiving long term TPN is desirable. Supplementation should be adjusted accordingly.

**Occupational exposure.** Occupational exposure is monitored by measuring urinary excretion of chromium with results corrected for creatinine content of the urine.

**References**


